Development of mutations in HIV-1 PR hinders the activity of antiretroviral drugs, forcing changes in drug prescription. Most resistance assessments used to date rely on expert-based rules on predefined sets of stereotypical mutations; such information-driven approach cannot capture new polymorphisms nor be applied for new drugs. Computational modeling could provide a more general assessment of drug resistance, and could be made available to clinicians through the Internet. We have created a protocol involving sequence comparison and all-atom protein-ligand induced fit simulations to predict resistance at the molecular level. We first compared our predictions with experimentally determined IC 50 of darunavir, amprenavir, ritonavir and indinavir from reference PR mutants displaying different resistance levels. We then performed analyses on a large set of variants harboring more than 10 mutations. Finally, several sequences from real patients were analyzed for amprenavir and darunavir. Our computational approach detected all genotype changes triggering high-level resistance, even those involving a large number of mutations.
INTRODUCTION
Antiretroviral therapy (ART) is one of the most effective interventions in medicine and, in particular, in HIV treatment. In ideal conditions of treatment, ART transforms a deadly disease into a chronic pathology, allowing patients to achieve life expectancy 1 and quality similar to that of non-HIV-infected individuals. 2, 3 Such efficacy, however, can be offset by HIV's ability to develop mutations conferring antiretroviral resistance in the presence of drug selective pressure [4] [5] [6] [7] and by patient-to-patient transmission of resistant viruses. In resource-limited settings, where the HIV/AIDS toll is higher, ART is often provided without virological monitoring, 8, 9 which is being associated with an alarming increase in drug resistance. [10] [11] [12] Antiretroviral drug resistance testing is key for clinical management 13 and epidemiologic surveillance, 1, [10] [11] [12] 14 but it is not trivial to assess. To this aim, we find multiple predictions techniques using molecular modeling 15, 16 and bioinformatics tools. [17] [18] [19] [20] [21] These, however, often fail when addressing real patients sequences containing a large number of mutations and/or new ones. Thus, caregivers often rely on expert-based rules to interpret predefined sets of stereotypical mutations. Such procedure assigns susceptibility scores to different drugs for each mutation encountered after sequencing, from a previously defined list; individual mutation scores are then added into a global score for each drug and combination of drugs. Such scores are usually translated into a susceptible-intermediate-resistant (SIR) interpretation. Interpretation rules based on a predefined list of mutations rely on previous knowledge and are limited in the mutation scope, so they cannot take into account the effect of non-predefined polymorphisms, mutational interactions, or mutation effects on different genetic backgrounds in the virus. Moreover, interpretation rules may initially provide limited resistance assessment to new molecules inhibiting the same target/s until new knowledge is generated.
In an attempt to build a universal computational tool for resistance prediction that would not rely on prior knowledge on drug resistance, we have developed an automatic protocol combining sequence alignment with protein-ligand induced fit sampling techniques. In this first proof-of-concept study we focused on the HIV-1 PR, but the process could be later extended to other enzymes, HIV-1 subtypes or viruses.
HIV-1 protease (PR) is a 22 kDa dimeric aspartic protease that contributes to the maturation progress of the virus, cleaving the polyprotein precursor into functional viral proteins. Being one of the main targets in the treatment against HIV, the development of nine FDA-approved protease inhibitors, along with numerous crystal structures were established in the last two decades. 22, 23 The active form of HIV-1 protease is a homodimer, with ~99 residues per chain. The catalytic residues Asp25 and Asp125 lie at the bottom of the binding cavity shielded by a pair of flaps (residues 44-55 and 144-155). 24 Main features common to all inhibitors are the existence of a hydroxyl group in contact with Asp25/125 residues, and a water molecule that mediates contact between a conserved carbonyl of the inhibitors and the protease amide groups of Ile50/Ile150 located in the flaps (Figure 1 ). Several resistant mutations have been described along the whole protease chain. Many mutations might occur simultaneously within a single variant highlighting the importance of complex cooperative effects. Typically these changes confer resistance not only by direct contact with the inhibitor, but also by subtle changes in the structure/dynamics incidentally affecting the active site. In addition to reducing or blocking drug inhibition, these mutations may also affect viral fitness by affecting the normal function and lead to the emergence of addition compensatory mutations that restore viral fitness. 
METHODS

Systems used
References structures
To build the homology models of the wild type NL4-3 and HXB2 reference sequences (which were considered as non-resistant genotypes unaltered by the selective pressure of any PI), we used the crystal structure of HIV-1 protease bound to BE6 inhibitor (pdb code 1W5Y 32 ), with only 2 and 1 mutations per chain, respectively.
Several crystal structures with measured catalytic activities were also used to tune our computational protocol. For the APV ligand, the PDB entries used were: 3NU3 33 
Modeling HIV-1 protease mutants
Due to the strong correlation between sequence similarity and structure, our strategy to model mutants with no solved structure was to use the closest existing crystal structure in terms of sequence. We found ~450 crystal structures of HIV-1 protease which can be used as templates for building a given clinical sequence. Thus, modeling mutants was performed in two steps: (1) a search for the crystal structure with the highest similarity to the mutant sequence using BLAST, 36 and (2) building our model by replacing each mutant using the Maestro 37 software. Mutations were introduced simultaneously in the two protease chains.
Using this procedure several sets of mutants were built: The first set was selected from the work by Koh et al., 31 were three NL4-3 variants: (L10I, G48V, I54V, L90M), (L10F, V32I, M46I, I54M, A71V, I84V) and (L10F, D30N, K45I, A71V, T74S) were tested against four inhibitors DRV, APV, indinavir (IDV) and ritonavir (RTV). The second set was obtained from the study by Shenderovich et al. 15 For this case, we selected the more difficult set of sequences, with more than 10 mutations (and a maximum number of 17 mutations per monomer, giving a total of 15 sequences) against IDV inhibitor. The third set included 21 and 23 PR FASTA sequences with different resistance profiles to APV and DRV, respectively, obtained from routine genotypic resistance testing (TRUGENE® HIV-1 Genotyping Assay, Siemens Healthcare, Barcelona, Spain) in the HIV Unit and irsiCaixa AIDS Research institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. This last set of studies was performed as a blind test, where the modeling team had only access to the sequence but not to the resistance score.
Systems preparations
All systems were prepared with Schrodinger's Protein Wizard. 37 This algorithm builds hydrogen-bonded clusters and performs 100000 Monte Carlo moves by reorienting hydroxyl and thiol groups, water molecules, amide groups of Asn and Gln, and the imidazole ring of His, to correct for typical crystal structure refinement errors. The algorithm also predicts protonation states of His, Asp, Glu, Lys and Arg. Each possibility is scored based on the total number of hydrogen bonds and their quality (relative to an idealized hydrogen bond). In this work, Asp25 was protonated in all structures, whereas Asp125 was considered ionized. Histidines 69 and 169 were either epsilon or double protonated depending on the structural environment; all other histidines kept delta protonation. A water molecule, generally found in all protease-inhibitor crystal structures was kept. The water preserved mediates a contact between the P2/P1′ carbonyl oxygen atoms from the inhibitors and the amide groups of Ile50/Ile50′.
Once the atom model was built, the ligand was initially docked in the active site using Glide. 38 The top score model (XP scoring) obtained by glide was selected, followed by a molecular mechanics minimization using Schrodinger's Protein Wizard and the OPLS2005 force field to remove possible geometric clashes. In order to keep the system close to its initial geometry, a restrain was applied to all heavy atoms (allowing a maximum displacement of 0.3 Å). All ligands were quantum mechanically minimized separately in the gas phase using the DFT/B3LYP and 6-31G** basis set level of theory. Atomic charges were then derived from the electrostatic potential fitting at the same level of theory. Additional ligand parameters were taken from the OPLS2 force field.
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Assessing the induce fit and binding energy
To map the protein-ligand conformational space we used PELE 29 , which implements a
Monte Carlo algorithm where new trial configurations are produced with sequential ligand (and protein) perturbation, side chain prediction and minimization steps. Ligand perturbation includes a ligand specific rotamer library. 30 Trial configurations are then filtered with a Metropolis acceptance test, where the energy is described with an all-atom OPLS force field and a surface generalized born solvent model. 40 PELE has recently shown to provide competitive advantages with respect to state of the art induced fit commercial software and to reproduce the conformational sampling obtained in microsecond molecular dynamics (MD) trajectories. 41, 42 A total of 12 independent MC trajectories were produced for each inhibitor and mutant sequence. Trajectories were interrupted after 12h of CPU, providing approximately a total of 6000 Monte Carlo steps and ~2000 accepted minima. PELE's binding energy was then obtained by averaging the interaction energies of all accepted minima (approximately 2000 snapshots). The overall protocol has been added to our in-house server (pele.bsc.es) for public usage. In addition to PELE, HIV-1 resistance to APV and DRV was modeled with MD, using the Amber 12 software. 43 For each system we performed 10 independent 10 ns runs with explicit waters, a 10 Å layer of pre-equilibrated water molecules in a truncated octahedral box, and physiological salt (NaCl) conditions. A time step of 1 fs was used throughout the simulations in combination with the SHAKE algorithm to constrain bond lengths involving hydrogen atoms. 44, 45 Non-bonded interactions were explicitly evaluated for distances below 9 Å. The particle mesh Ewald method was employed to treat long-range electrostatic interactions. 46 Constant pressure and temperature (NPT ensemble) were maintained by weakly coupling the system to an external bath at 1 bar and 298 K, using the Berendsen barostat and thermostat. 47 Finally, MMPBSA.py 48 was used to extract the average binding energy, where we tried several time ranges: 1, 5 and 10 ns; best results were obtained using 20 snapshots between 3 and 5 ns.
RESULTS
In the first part of the study, we validated the method by comparing in vitro IC 50 results for specific mutations with our theoretical predictions. In the second part, attention was centered on predicting how mutations in HIV-1 protease taken from real patients affect drug resistance against APV and DRV.
Validation for the set of data with known experimental binding affinity (IC 50 )
We first calculated the interaction energies of APV, DRV, IDV and RTV for three different sequences (each ligand) among the set described in Koh et al. 31 Besides NL4-3, for each drug we selected the mutation with the lowest and highest IC 50 value relative to the value for NL4-3 (see Table 3 in Koh et al. 31 ). Figure 2 , summarizes PELE's relative increase in binding energy for each ligand and target, compared to the reference NL4-3 (the higher the increase in binding energy, the greater the resistance conferred by the mutation). The experimental relative (with respect to NL4-3) increase in IC 50 is also shown with numbers in Figure 2 . Clearly, PELE's simulations can distinguish between the high (dark gray) and low (light gray) resistance mutant in each specific inhibitor. Moreover, the relative increase in PELE's binding energy correlates nicely with the experimental increase in resistance in this set of data. This is more clearly seen in the right panel where the natural logarithm of the IC50 values is used to estimate changes in binding affinities. For a second test, we used a subset of sequences derived from the work of Shenderovich et al. 15 Using known and in-house prepared mutations, these authors developed possibly the most comprehensive computational predictor to date. However, as noticed by the same authors, the quality of predictions correlates negatively with the increase of number of mutations. From their test set, we selected all the sequences with more than 10 mutations for the IDV inhibitor (a total of 15 sequences, which represent a specially difficult set for prediction 15 ). Figure 3 shows the correlation between our relative interaction energy estimates, using again NL4-3 as the reference zero value, and the experimental relative binding energy. Additionally we include the estimates derived from Shenderovich et al. 15 , also referred to NL4-3. We should notice that in Shenderovich et al., all mutant models were derived from one crystal and that they used simpler side chain (and backbone) sampling algorithms. Despite the difficulty of this set of 15 compounds, the method outlined here shows a coefficient of determination equal to 0.75 (PELE's p-value= 2.5e -05
and ∆E's p-value = 0.004), improving the previous result significantly. 
Prediction results for APV and DRV
After testing our computational protocol with publicly available data, we proceeded to perform "blind predictions" of the resistance in clinical samples. Importantly, each of these variants, taken from HIV infected patients, contained a large number of mutations in each monomer (10-25) when compared to the reference NL4-3. Therefore, in some of the simulated systems the protease bore as many as 50 mutations, representing an incredible difficult test (see Figure S1 in Supporting Information (SI) for the alignment of each sequence to the subtypeB consensus protease sequence). The data for the clinical isolates was divided (and ordered) based on the resistance scores calculated from expert assessments in HIVdb 49 . Samples were categorized as sensitive (S) when HIVdb resistance scores were below 20, intermediate (I) resistance when scores were between 20 and 60, and resistant (R) when scores were 60 or higher. Figure 4 shows the results for APV where again we computed PELE's relative binding energies to the reference compound NL4-3. For this compound we had initially run a benchmark with four variants containing known resistance-related mutations: two consensus reference proteins (the sequence from pdb structure 3NU3 and the reference sequence HXB2, which were both considered non-resistant), the single mutation I50V with 30 fold increase in K i (pdb id 3NU5) and the triple mutant V32I/I47V/V82I with 15 fold increase in K i (pdb id 3S43). The data from this benchmark has also been included in Figure 4 (left-hand side). As can be seen, the two additional non-resistant reference sequences (the one from 3NU3 and HXB2) show equal or (slightly) better interaction energies to that found for NL4-3. This result shows how our computational protocol predicts reference sensitive sequences other than NL4-3 as sensitive, and similarly, the two APV-resistant reference sequences (3S43 and 3NU5), with a 15 and 30 fold increase in K i , respectively, were correctly predicted as interfering drug-binding (note that the impact of the mutation in predicted binding, matches the relative K i increase found experimentally).
For the sequences extracted from the patients (1-21) , it can be seen that all sensitive sequences (green, columns 1-7) are predicted to be sensitive by our method, and all highly resistant sequences are predicted to be highly resistant (red, columns 14-21). Sequences classified as intermediate resistance (in yellow) offer a less clear differential profile, but there is only one pair (13/14) where PELE will have some difficulty to predict the resistance level produced by the mutation. Important residues, discussed in the main text, are underlined in red circles. Partial sequence alignment to NL4-3 is also shown for both systems. Figure 6 shows the equivalent results for DRV. For this compound we also modeled three additional variants containing known resistance-related mutations: two consensus reference proteins (the one taken from pdb structure 2IEN and the reference sequence HXB2) and the double mutant I50L/A71V (3M60), which has 4 fold higher dissociation constant. As in the APV case, reference and sensitive compounds show little or no effect when compared to NL4-3. Again, the most remarkable result is the correlation between the predicted relative binding energy and the estimation of resistance, where all highly resistant variants are clearly identified. 
DISCUSSION
The primary aim of this study was to develop an automatic computational protocol for rapid discrimination between resistant and sensitive HIV-1 protease variants. To this aim we have used PELE, an atomic-resolution sampling algorithm combining a stochastic Monte Carlo procedure with protein structure prediction techniques, which is specially suited for induced-fit docking problems. 41, 42 Since most of the mutant structures have not been crystallized, one of the main questions is how to generate an all atom model for each sequence. Since we were comparing the binding energies to the NL4-3 reference sequence, one simple strategy would have been to use its structure as a template (in Modeller, 50, 51 I-TASSER, 52 etc.). However, most sequences have up to 20 mutations (when compared to NL4-3) in each chain, which could introduce large errors in building the models; the large number of HIV-1 X-ray crystal structures enabled better strategies. An obvious one is the use of multiple templates in homology modeling, but our initial analysis indicated that it is better to start from a well-defined single template than to combine different crystal structures. Thus, we decided to create a subset of several crystal structures to which our sequences were compared and to use the crystal structure with the best sequence alignment to our target (to minimize the number of mutations modelled) as template. By doing so, we reduced significantly the number of mutations for model building (see Table S1 in SI for a list of the reference crystal structures).
Our initial two tests compared the predicted relative binding energy with systems having experimental affinities. As seen in Figures 2 and 3 , PELE is capable of distinguishing between resistant and sensitive sequences. Moreover, it shows a good correlation to experimental affinities even for sequences with a large number of mutations, improving existing theoretical prediction tools. Next, we tested our protocol in a blind test with patient sequences for two well-known HIV-1 inhibitors, APV and DRV. The results showed again noteworthy correlations between calculated changes in binding energy and the index obtained by HIVdb scores. In all cases we could distinguish the sequences with strong resistance, having predicted relative binding energies >5kcal/mol. This value is also consistently being observed in the initial two tests. The method showed problems to discriminate between mutants with moderate resistance, but this is the segment where rulebased methods (used here as reference) are expected to show the poorest performance. MD/MMPBSA predictions, on the other hand, have difficulties in predicting high resistance mutants. This behavior, however, is expected since this method works efficiently when addressing small changes (involving mostly single and double mutants).
16, 53
The majority of resistance-related mutations are conservative substitutions in positions Leu10, Val32, Ile54, Val82, Ile84 and Leu90. Our simulations indicated that these mutations do not introduce large changes in the structure of the complex, but modify subtle van der Waals and hydrogen bond interactions between the ligand and active site amino acids (see Figure 5 ). Such resistance mechanisms are observed for other systems, 54, 55 and agree with the fact that none of these mutations significantly disrupts enzyme activity. However, even small, the subtle conformational changes induced by mutations are important in defining accurate binding, making it necessary the use of specific homology models and induce fit relaxation. The later point is clearly shown by the fact that PELE's scores after homology modeling (or after only a short exploration of sampling) did not correlate with susceptibility data (Table 1 ). The quality (and necessity) of the induced fit conformational sampling is also evident when predicting the interaction with a general scoring function. For this, we used Glide XP from Schrodinger. 38 Figure 7 shows relative Glide scores before and after the induced fit for the 21 clinical sequences in APV (plus NL4-3 and HXB2). Each score is the average of 50 structures obtained after clustering PELE's trajectories. Clearly the correlation with HIVdb scores significantly improves after conformational sampling with PELE. While the final Glide scores still have low correlation, 0.33, they can identify most of the high resistance sequences. Remarkably, the correlation increases to 0.80 when using PELE's all-atom binding energy (as score), revealing the importance of an explicit treatment of all-atom interactions. 30 Notice also that the clustering procedure only reduces the overall PELE's correlation from 0.82 to 0.80. First-score
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Conclusions
Overall, this study shows how computational techniques are capable of quantitatively discriminating resistance variants of HIV-1 protease. Our protocol, combining sequence alignment to current pdb structures and state of the art protein-ligand induced fit sampling algorithms, shows great promise as an automatic tool for a quick prediction. The entire protocol can be run in less than 24 hours on a small commodity workstation, and is based on biophysical first principles. Moreover, it is capable to trace the effect of novel mutations and the binding of new drugs. In summary, modeling drug-target interactions holds the potential to provide less biased and more accurate assessments of antiretroviral drug resistance, which could improve clinical management of HIV-infected subjects.
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